Clarivate

DECEMBER 6, 2022

In a fiercely competitive U.S. healthcare provision landscape, integrated delivery networks, or IDNs, are differentiating their offerings by adding outpatient treatment centers, pursuing National Cancer Institute designations and investing in value-based care. Christopher Silva, Senior Healthcare Research Analyst.

Networking 52

Networking Healthcare Healthcare Competition 52

MedCity News

JUNE 16, 2023

Regardless of the reasons, investors, pharma, and research organizations are recognizing that advanced digital health tools will be a significant competitive advantage and generate meaningful return on investment (ROI) in an industry that is becoming more personalized and specialized.

Pharma 100

Pharma Food and Drug Administration Recruitment Pharmacology 100

Pharmaceutical Technology

JUNE 15, 2023

Learn about how AI is helping companies right now, what to know about its benefits and challenges, and what’s needed to implement AI in biopharma research. AI and its healthcare applications will continue to evolve, but you can already realize many potential benefits. How is AI used in the pharmaceutical industry?

Pharma 52

Pharma Management Networking Manufacturing 52

European Pharmaceutical Review

DECEMBER 21, 2022

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero.

Manufacturing 75

Manufacturing Pharmaceutical Healthcare Healthcare 75

Clarivate

MAY 24, 2023

In recent years, FDA has increasingly shown an openness to surrogate endpoints as the basis for approval of a therapy,” said Bethany Kiernan, Director of Healthcare Research Analytics for Infectious, Niche and Rare Diseases at Clarivate.

Patients 52

Patients Food and Drug Administration Biopharma FDA 52

Pharmaceutical Technology

JANUARY 25, 2023

Although expert opinions differ on the future of special purpose acquisition companies (SPACs), some companies are continuing to explore their use. In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. Download our free whitepaper.

Marketing 69

Marketing Biopharma Pharma Competition 69